Glucored Forte Tablet is a combination oral hypoglycemic agent containing Glibenclamide 5 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glibenclamide, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in enhanced glucose uptake and utilization. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet, exercise, or monotherapy. Glucored Forte is typically prescribed as part of a comprehensive diabetes management plan including dietary modifications and regular physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia due to Glibenclamide. Regular monitoring of blood glucose levels, renal function, and periodic assessment of hematological parameters is recommended during therapy. Dose adjustments should be individualized based on patient response and tolerability. Glucored Forte Tablet should be used under strict medical supervision to optimize therapeutic outcomes and minimize potential risks.